Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on Idiopathic Pulmonary Fibrosis, a condition where the lung tissue becomes thick and scarred over time, making it difficult to breathe. The purpose of the study is to evaluate the effectiveness and safety of a drug called BMS-986278, also known as admilparant, which is an LPA1 antagonist. Participants in the study will receive either the study drug in the form of a film-coated tablet taken by mouth or a placebo.

During the study, researchers will monitor how the treatment affects the lungs, specifically looking at changes in Forced Vital Capacity, which is a measure of the total amount of air a person can exhale after taking a deep breath. The study also observes how the condition changes over time and examines the distance a person can walk during a 6-minute walk test, which is a common way to check physical fitness and lung function. The investigation will take place over a period of 52 weeks.

The research process

The trial runs in 2 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    <b>medication administration</b>

    You will receive either the test medication, known as admilparant, or a placebo, which is an inactive substance that looks like the medication. the placebo is used as a comparison to see how effective the admilparant is.

    The admilparant is provided as a film-coated tablet to be taken by oral use (swallowed). the specific dosage is 9999 milligrams.

  2. Step 2

    <b>study monitoring and evaluation</b>

    The study lasts for a total of 52 weeks.

    During this period, the forced vital capacity (fvc), which is a measurement of the amount of air your lungs can hold, is monitored to observe any absolute change from the start of the study.

    Other assessments include measuring the walking distance through a 6-minute walk test (6mwt) to check for changes in physical capability.

    The progression of the disease is also tracked from day 1 through the 52-week mark.

Who can join the trial?

8 criteria

  • You must be at least 40 years old when you sign the study agreement.
  • You must have a diagnosis of idiopathic pulmonary fibrosis, which is a condition that causes scarring in the lungs, within the last 7 years.
  • Your diagnosis must be confirmed by a high-resolution computed tomography (HRCT), which is a special type of detailed X-ray scan used to look closely at the lungs.
  • The scan must show evidence of usual interstitial pneumonia, a specific pattern of lung scarring.
  • If you are currently taking the medications pirfenidone or nintedanib, you must have been taking a steady, unchanging dose for at least 90 days.
  • If you are not taking pirfenidone or nintedanib, you must not have taken either of these medicines in the 28 days before joining the study.
  • Women who are able to become pregnant must use a highly effective form of contraception (birth control) and must have a negative pregnancy test through urine or blood before starting.
  • Men who are sexually active with women who can become pregnant must agree to use male barrier contraception, such as a condom.

Who cannot join the trial?

6 criteria

  • Having a history of a stroke (when blood flow to part of the brain is interrupted) or a transient ischemic attack (a temporary period of symptoms similar to a stroke that resolves quickly) within the 3 months before the study starts.
  • Showing signs or symptoms of heart failure (a condition where the heart cannot pump enough blood to meet the body's needs) while resting.
  • Having a current malignancy (a type of cancer that is currently present in the body).
  • Having a previous malignancy (a history of cancer) that has returned within the last 2 years.
  • Having a biopsy (a medical procedure where a small sample of tissue is removed) that shows signs of possible cancer that cannot be ruled out.
  • Having interstitial lung disease (a group of disorders that cause scarring or inflammation in the lungs) caused by known specific factors, such as hypersensitivity pneumonitis (lung inflammation caused by breathing in certain dusts or chemicals), autoimmune associated ILD (lung disease caused by the body's immune system attacking its own tissues), or sarcoidosis (a disease that causes small clumps of inflammatory cells to form in the lungs).
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruitingNot recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Admilparant is an experimental medication taken by mouth in tablet form. It is being studied to see if it can help improve lung function in people living with a condition called idiopathic pulmonary fibrosis.

What is already known about the treatment

Admilparant - This medication is taken as a film-coated tablet by mouth and is currently being studied in clinical trials for its potential use in treating lung scarring diseases like idiopathic pulmonary fibrosis. As an LPA1 antagonist, it works by blocking specific receptors on the surface of cells that respond to a certain fat-like molecule, which helps prevent the overactive cell signaling that leads to tissue scarring. This drug belongs to a class of medicines designed to interrupt the biological pathways responsible for progressive lung damage.

Investigated diseases

Idiopathic pulmonary fibrosis - This is a condition where the lung tissue becomes thick and scarred over time. This scarring makes it difficult for the lungs to function properly. As the disease progresses, the lung tissue becomes increasingly stiff. This stiffness makes it harder for the lungs to expand and contract during breathing. The scarring typically develops gradually within the lungs.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-503697-21-01Protocol codeIM027068Estimated enrolment1 201 patientsSponsorBristol-Myers Squibb Services Unlimited Company

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).